Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis

Phase 2

Terminated

Brief Summary: The present study has been designed in order to evaluate the efficacy and safety of two doses of Givinostat in subjects with polyarticular course JIA

Givinostat ready-to-use suspension especially intended for paediatric administration, will be administered orally at different daily doses.

Patients with an established diagnosis of one of the following JIA forms (Polyarticular JIA rheumatoid factor positive or negative, Oligoarticular extended JIA, Systemic JIA without active systemic features) will be enrolled.

The treatment regimen will remain unchanged for 12 weeks and the clinical response will by assessed by applying the ACR Pediatric response criteria. Patients achieving at least an ACR Pediatric 30 response will continue receiving the assigned dose for 12 further weeks.

After the end of study (week 24) responder patients will be allowed to extend the treatment until they maintain a clinical benefit.

Detailed Description: Non-clinical data on Givinostat, support a potent anti-inflammatory mechanism of action which can potentially slow the arthritic destructive process. This rationale seems to be confirmed by the preliminary evidences collected in a previous Phase II clinical trial conducted in children and young adults with systemic JIA.

The present protocol is aimed at collecting new information on safety and efficacy of two doses of Givinostat for the treatment of JIA.

Recruitment & Eligibility

Inclusion Criteria

patients of both genders, aged 2 to 17 years, with established diagnosis of polyarticular course Juvenile Idiopathic Arthritis (see before for specific subtypes) according to ILAR (International League Against Rheumatism) criteria (Petty RE et al., 2004) for at least six months before the study entry
age at polyarticular JIA diagnosis < 16 years
active disease for at least 6 months prior to enrolment as defined by the following criteria:
presence of at least 5 active joints (those with swelling or, in the absence of swelling, limited range of motion accompanied by pain/tenderness)
inadequate response to, or intolerance to, at least one biologic agent such as, but not limited to, etanercept, inﬂiximab, and adalimumab.
maximum allowed steroid dose 0.2 mg/kg/day or 10 mg/day (whichever is lower) of prednisone or equivalent
in case of concomitant methotrexate treatment, it has to be on a stable dose ≤15 mg/m2 weekly for at least 1 month before patient's enrolment
other disease-modifying anti-rheumatic drugs possibly previously introduced have to be discontinued for a period of at least five half-lives
concomitant nonsteroidal anti-inflammatory drugs, if any, on a stable dose for at least four weeks before patient's enrolment

Exclusion Criteria

patient with fever related to JIA or other systemic features of JIA during 12 months before entering the study
active bacterial or mycotic infection requiring antimicrobial treatment
episode of macrophage activation syndrome in the last 6 months
a baseline prolongation of QT/QTc interval, use of concomitant medications that prolong the QT/QTc interval or history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) (Appendix C)
clinically significant cardiovascular disease
clinically significant illness i.e. any condition (including laboratory abnormalities) that in the opinion of the Investigator places the patient to unacceptable risk for adverse outcome if he/she were to participate in the study
psychiatric illness/social situations that would limit compliance with study medication and protocol requirements
inherited metabolic diseases
presence of malignancy
pregnancy or lactation
positive blood test for HIV
active EBV infection, active B and/or C hepatitis
platelet count <100x109/L
absolute neutrophil count <1.5x109/L
serum creatinine >2xULN (Upper limit of normal).
total serum bilirubin >1.5xULN.
serum AST/ALT > 3xULN.
congenital heart and/or central nervous system disorders

Arm && Interventions

Group	Intervention	Description
Givinostat 1.0 mg/kg daily	Givinostat	-
Givinostat 1.5 mg/kg daily	Givinostat	-

Primary Outcome Measures

Name	Time	Method
ACR Pediatric Response Level (ACRPRL) 30 After 12 Weeks of Treatment	12 weeks of treatment	ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0-100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 30 of response, defined as a 30% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%

Secondary Outcome Measures

Name	Time	Method
ACR Pediatric Response Level (ACR 50, 70, 90 and 100) at Week 12	at week12	ACR Pediatric variables include: Physician's Global Assessment of disease activity on a 0- 100 mm visual analogue scale from 0 mm = no disease activity to 100 mm = very severe disease activity; Parent's or patient's Global Assessment of Patient's overall well-being on a 100 mm VAS from 0 mm = very well to 100 mm = very poor; Functional ability: Childhood Health Assessment Questionnaire; Number of joints with active arthritis using the ACR definition (any joint with swelling, or in the absence of swelling, limitation of motion accompanied by pain/tenderness not due to bone deformity); Number of joints with limitation of motion; Laboratory measure of inflammation: C-reactive protein (mg/L) Patients were considered as responders if they achieve at least an ACR Pediatric Criteria level 50, 70, 90 and 100 of response, defined as a 50%, 70%, 90% and 100% improvement as compared to baseline in at least 3 of the 6 variables listed above, with no more than 1 variable worsening by \> than 30%

Locations (13): Ospedale Meyer
🇮🇹
Firenze, FI, Italy
Azienda Ospedaliera-Università di Padova
🇮🇹
Padova, PD, Italy
Mother and Child Health Institute "Dr Vukan Cupic"
🇷🇸
Novi Beograd, Belgrade, Serbia
University Clinical Center Nis
🇷🇸
Nis, Serbia
1st Faculty of Medicine and General Faculty Hospital
🇨🇿
Praha 2, Praha, Czech Republic
Policlinico G. Martino
🇮🇹
Messina, ME, Italy
Spitalul Clinic de Urgenta pentru Copii "M.S. Curie"
🇷🇴
Bucarest, Romania
Institute of Rheumatology Belgrade
🇷🇸
Belgrade, Serbia
Universitair Ziekenhuis Gent
🇧🇪
Gent, Belgium
Institutul pentru Ocrotirea Mamei si Copilului "Alfred Rusescu"
🇷🇴
Bucarest, Romania
Istituto Gaetano Pini
🇮🇹
Milano, MI, Italy
Hospital Ramón y Cajal
🇪🇸
Madrid, Spain
Children's Hospital - University Medical Centre Ljubljana
🇸🇮
Ljubljana, Slovenia